A Comparison of the Efficacy of Dapagliflozin Metformin Versus Sitagliptin Metformin: in Newly Diagnosed Type 2 Diabetes
Afra Ishtiaque, Shahreen Mehmood Khan, Salman Azhar, Mehreen Mehmood, Saira Shahnawaz
Abstract
Open-access reader
Afra Ishtiaque, Shahreen Mehmood Khan, Salman Azhar, Mehreen Mehmood, Saira Shahnawaz
Abstract
Open-access reader
Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective: To comparison of the efficacy of dapagliflozin+metformin versus sitagliptin+metformin: in newly diagnosed type 2 diabetes Methodology: In this Randomized Control Trial, we enrolled a total of 180 cases; 90 cases newly diagnosed type 2 diabetes mellitus (HbA1c>6.5) in two equal groups A&B on the basis of computer-generated randomization table. Group A was allotted to the cases 100mg q.d sitagliptin plus 850 mg in addition to 500mg metformin 2 times a day. Patients of Group B were advised for 10mg qd dapagliflozin+500mg metformin 2 times a day for six months. Patients were followed up on monthly basis for any inconvenience. The final follow-up was done on 6th month of treatment. All the patients with poor/non-compliance were excluded from the study. All cases with HbA1c <6.0 were considered as effectively treated patients. Results: Comparison of Efficacy in both groups shows 44(48.9%) in Group A and 31(34.4%) in Group B, the overall efficacy was 41.7%, p-value=0.0.35 showing a significant difference. Conclusion: Dapagliflozin+metformin is significantly higher than sitagliptin+metformin for newly diagnosed type 2 diabetes Keywords: Newly type 2 diabetes, treatment, Dapagliflozin & Metformin Vs Sitagliptin & Metformin
Key concepts: Metformin, Dapagliflozin, Sitagliptin, Medicine, Type 2 diabetes, Internal medicine, Diabetes mellitus, Type 2 Diabetes Mellitus